Jefferies raised its price objective on Aflac shares, while Barclays and TD Cowen issued rating updates.
1 report, 1 independent
Updated Mon 00:00
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Jefferies raised its price objective on Aflac shares, while Barclays and TD Cowen issued rating updates.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Aflac
largest provider of supplemental insurance in the United States
Nothing else this week.
-
Jefferies Financial Group
American financial services company
- Acrivon Therapeutics, focusing on RAS-driven cancers, is listing shares on Nasdaq, with Jefferies providing investment research.
- Jefferies Financial Group raised its shares to strong-buy rating, while Citigroup raised its shares to outperform rating, and Norges Bank bought a new position in Essex Property Trust, Inc.
-
Barclays
British bank
-
TD Cowen
American investment bank
Related events
- Multiple financial firms, including Jefferies, Bank of America, and Raymond James, issued price objective and rating updates on October 23, 2026.
- Morgan Stanley and Jefferies Financial Group adjusted price targets and ratings for Lincoln National Corporation.
- Morgan Stanley, Jefferies, and Citigroup commented on Cullen/Frost Bankers, boosting targets and issuing sell/underweight ratings on July 25, 2026.
- Financial firms, including Jefferies, RBC, and Wells Fargo, issued rating and price objective updates for Biogen.
- Analyst firms Jefferies, TD Cowen, and Raymond James Financial provided rating updates for Black Diamond Therapeutics, alongside MarketBeat consensus data.